当基因测序遭遇质疑,“功能性”精准医学赋予癌细胞更大的使命

2018-02-23 智康 MedSci原创

浅谈“功能性”精准医学在当下肿瘤临床治疗的必要性

精准医学(Precision medicine)是近来热度非常高的一个词汇。得益于基因测序技术的进步,它萌发于学术科研中心,应用在生物医药产业,更是广泛出现在各大新闻媒体当中为百姓所熟知,甚至一度成为了最热门的政治口号。然而,由于癌细胞基因的不稳定性,仅仅采用基因测序这种间接方式,在大多数情况下并不足以给出最合理的用药方案。而精准医疗不仅仅是基因测序,还包括了多层面医疗技术的使用。对个体的肿瘤细胞进行干预或扰动,从而得到重要的功能性信息,这是功能性精准医学的特点。比如基于CR(条件性重编程conditional reprogramming)原理的新一代肿瘤原代细胞培养技术对候选药物或药物组合进行精确的药理分析和药效检测,进而指导临床用药,也将成为一种更为直接、更为准确的肿瘤诊治模式。到底什么是精准医学?也许最直接的回答可以是“找到与每一位患者匹配度最高的用药方式的过程”。具体到癌症精准医学领域,也许可以理解为“根据每一位患者的不同情况,找到最大程度减小肿瘤体积或者清除患者肿瘤的治疗方法”。2015年美国联邦政府首次提出2016精准医学倡议以及2020癌症登月计划。同年,世界上相继有很多

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1915471, encodeId=e90419154e1e0, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jan 27 00:22:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708186, encodeId=d8901e0818697, content=<a href='/topic/show?id=bd5226e986d' target=_blank style='color:#2F92EE;'>#使命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26798, encryptionId=bd5226e986d, topicName=使命)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21a31549739, createdName=ms920641618706883, createdTime=Wed Mar 07 03:22:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735117, encodeId=97981e35117a6, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Tue Jul 10 02:22:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252473, encodeId=1b0112524e33c, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Feb 25 07:22:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403291, encodeId=0c3c14032910f, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Feb 25 07:22:00 CST 2018, time=2018-02-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1915471, encodeId=e90419154e1e0, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jan 27 00:22:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708186, encodeId=d8901e0818697, content=<a href='/topic/show?id=bd5226e986d' target=_blank style='color:#2F92EE;'>#使命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26798, encryptionId=bd5226e986d, topicName=使命)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21a31549739, createdName=ms920641618706883, createdTime=Wed Mar 07 03:22:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735117, encodeId=97981e35117a6, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Tue Jul 10 02:22:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252473, encodeId=1b0112524e33c, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Feb 25 07:22:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403291, encodeId=0c3c14032910f, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Feb 25 07:22:00 CST 2018, time=2018-02-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1915471, encodeId=e90419154e1e0, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jan 27 00:22:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708186, encodeId=d8901e0818697, content=<a href='/topic/show?id=bd5226e986d' target=_blank style='color:#2F92EE;'>#使命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26798, encryptionId=bd5226e986d, topicName=使命)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21a31549739, createdName=ms920641618706883, createdTime=Wed Mar 07 03:22:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735117, encodeId=97981e35117a6, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Tue Jul 10 02:22:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252473, encodeId=1b0112524e33c, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Feb 25 07:22:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403291, encodeId=0c3c14032910f, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Feb 25 07:22:00 CST 2018, time=2018-02-25, status=1, ipAttribution=)]
    2018-07-10 saikp
  4. [GetPortalCommentsPageByObjectIdResponse(id=1915471, encodeId=e90419154e1e0, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jan 27 00:22:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708186, encodeId=d8901e0818697, content=<a href='/topic/show?id=bd5226e986d' target=_blank style='color:#2F92EE;'>#使命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26798, encryptionId=bd5226e986d, topicName=使命)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21a31549739, createdName=ms920641618706883, createdTime=Wed Mar 07 03:22:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735117, encodeId=97981e35117a6, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Tue Jul 10 02:22:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252473, encodeId=1b0112524e33c, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Feb 25 07:22:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403291, encodeId=0c3c14032910f, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Feb 25 07:22:00 CST 2018, time=2018-02-25, status=1, ipAttribution=)]
    2018-02-25 yxch36
  5. [GetPortalCommentsPageByObjectIdResponse(id=1915471, encodeId=e90419154e1e0, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jan 27 00:22:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708186, encodeId=d8901e0818697, content=<a href='/topic/show?id=bd5226e986d' target=_blank style='color:#2F92EE;'>#使命#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26798, encryptionId=bd5226e986d, topicName=使命)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a21a31549739, createdName=ms920641618706883, createdTime=Wed Mar 07 03:22:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735117, encodeId=97981e35117a6, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Tue Jul 10 02:22:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252473, encodeId=1b0112524e33c, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Feb 25 07:22:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403291, encodeId=0c3c14032910f, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Feb 25 07:22:00 CST 2018, time=2018-02-25, status=1, ipAttribution=)]

相关资讯

2018医生回扣严打,谁还在给医生送钱?

通过给回扣的方式促进药品在医院的销售,终究不是长久之计,风险也大,最终还是依靠专业能力和专业服务。

医药商业真正进入寒冬期

很多中小型医药商业企业由于被剥夺了配送资质,加上大型商业的蚕食挤压,而自身有没有专业的市场、销售功能,活的苟延残喘。

2018年医药营销趋势

2017年,国家新医改的政策对医药行业影响非常之大,让医药行业人士都感觉震惊、无奈和麻木。 国家政策对于医药营销层面,笔者史立臣分析了几个非常重要的方面

中医诊所即将井喷:经营风险也将加大

备案制将令中医诊所会井喷式增长,而这种增长主要是个体的中医诊所,并不是公立医疗结构中的中医诊所。

为什么很多中医诊所、中医馆都经营困难?

中医诊所、中医理疗馆、中医康复馆或中医馆如果想发展起来,绝对要走大众化路线,不能搞得像皇宫似得,吓走患者,更不能没特色。

2018年制药企业营销转型5步走

其实针对制药企业来说,两票制的压力在2017年下半年就非常明显的体现了,高开后,很多费用无法合规处理,而制药企业又没有更好的营销转型思路,所以,2018年的营销年度工作计划做起来非常困难。